Table 1 Clincal demograchics of enrolled patients regarding MPR status.
Characteristics | All patients (N = 40) | Patients with major pathological response (N = 15) | Patients without major pathological response (N = 25) | P-value |
|---|---|---|---|---|
Age —— yrs | 0.812 | |||
Mean ± SD | 58.7 ± 10.9 | 58.6 ± 9.9 | 58.7 ± 11.5 | |
Median (range) | 61 (25–75) | 60 (36–72) | 62 (25–75) | |
Gender —— no. (%) | 0.740 | |||
Female | 16 (40.0) | 5 (28.6) | 11 (44.0) | |
Male | 24 (60.0) | 10 (71.4) | 14 (56.0) | |
Smoking status —— no. (%) | 0.749 | |||
Never | 23 (57.5) | 8 (53.3) | 15 (60.0) | |
Former/current | 17 (42.5) | 7 (46.6) | 10 (40.0) | |
Clinical stage —— no. (%) | 0.580 | |||
II | 10 (25.0) | 5 (35.7) | 5 (20.0) | |
IIIA | 22 (55.0) | 7 (50.0) | 15 (60.0) | |
IIIB-IVA | 8 (20.0)* | 3 (14.3) | 5 (20.0) | |
Mutation features —— no. (%) | 0.587 | |||
EGFR alteration | 19 (47.5) | 8 (50.0) | 11 (44.0) | |
KRAS alteration | 9 (22.5) | 4 (28.6) | 5 (20.0) | |
Other mutations | 12 (30.0) | 3 (21.4) | 9 (36.0) | |
PD-L1 expression——no. (%) | 0.208 | |||
Negative | 9 (22.5) | 4 (26.7) | 5 (20.0) | |
1–49% | 7 (17.5) | 2 (13.3) | 5 (20.0) | |
≥50% | 15 (37.5) | 8 (53.3) | 7 (28.0) | |
Unknown | 9 (22.5) | 1 (6.7) | 8 (32.0) |
